Second-line treatment of advanced hepatocellular carcinoma: Time for more individualized treatment options?

During the initial treatment period, cabozantinib was associated with lower EQ-5D scores than was placebo, and following this early deterioration, differences between EQ-5D scores for cabozantinib and placebo were numerically smaller but did not reach statistical significance.

also in 111,027 other papers